Florida is currently home to 3825 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Nephrotic Syndrome Study Network
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: University of Miami Miller School of Medicine, Miami, Florida
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Recruiting
The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Hepatic Insufficiency, Healthy
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
Recruiting
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida
Conditions: Healthy
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Recruiting
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Miami, Miami, Florida
Conditions: Mantle Cell Lymphoma
Breathing Training and Exercise Capacity in Non-CFB
Recruiting
The purpose of this research is to investigate whether a home-based and health coach supported specific breathing and respiratory muscle training program improves the ability to exercise, the function of the lungs and breathing muscles, and general clinical status in people with non-cystic fibrosis bronchiectasis (non-CFB).
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
04/17/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Non-cystic Fibrosis Bronchiectasis
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
Recruiting
The purpose of this study is to investigate if a mediterranean diet and exercise program for Lymphoma patients during chemotherapy can improve treatment completion and reduce treatment-related side effects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Miami, Miami, Florida
Conditions: Non Hodgkin Lymphoma, Hodgkin Lymphoma
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Hem-Onc Associates of the Treasure Coast, Port Saint Lucie, Florida
Conditions: Breast Cancer
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Recruiting
This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week period post treatment after a single administration of SB-007.
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/16/2025
Locations: Bascom Palmer Eye Institute, Miami, Florida
Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
Recruiting
To evaluate the ability of a multidisciplinary and multisite group, the Pediatric Evolutionary Tumor Board (pedsETB), to develop additional therapeutic strategies in patients without curative options or with suboptimal outcomes.
Gender:
ALL
Ages:
All
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pediatric Cancer
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Recruiting
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Research site, Lake Mary, Florida
Conditions: Solid Tumors